Try the modernized beta website. Learn more about the modernization effort.
Working… Menu
Trial record 1 of 2 for:    motion xadago
Previous Study | Return to List | Next Study

MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist (MOTION)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00605683
Recruitment Status : Completed
First Posted : January 31, 2008
Last Update Posted : October 29, 2013
Information provided by (Responsible Party):
Newron Pharmaceuticals SPA

Brief Summary:

Parkinson's disease is a major neurodegenerative disorder in which there is a progressive loss of nigrostriatal dopaminergic neurons. The understanding that PD is a syndrome of dopamine (DA) deficiency led to the introduction in the clinical practice of L-dopa, a precursor of DA that crosses the blood brain barrier, and also to the use of selective inhibitors of MAO B, the major DA metabolising enzyme in man.

This is a double-blind, placebo-controlled, parallel-group, randomised, multi-centre, multi national, Phase III trial, comparing two doses of safinamide (50 and 100 mg p.o. q.a.m.) versus placebo as add-on therapy to a stable dose of a single dopamine agonist in subjects with early idiopathic Parkinson's Disease.

The principal efficacy measure, i.e., change in mean value of UPDRS - Section III total score from baseline to endpoint, was chosen based on regulatory guidance and prior use in other trials in similar populations.

Condition or disease Intervention/treatment Phase
Idiopathic Parkinson's Disease Drug: Safinamide (as add-on therapy) Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 679 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase III, Double-blind, Placebo-controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist
Study Start Date : November 2007
Actual Primary Completion Date : January 2012
Actual Study Completion Date : March 2012

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: 1
50 mg/day Safinamide
Drug: Safinamide (as add-on therapy)
Safinamide, (S)-(+)-2-[4-(3-fluorobenzyloxy) benzylamino] propanamide methanesulfonate, is an a-aminoamide derivative
Other Names:
  • Apokyn
  • Parlodel
  • Mirapex
  • Requip
  • Cabergoline (not approved in US)
  • Lisuride (not approved in US)
  • Pergolide (withdrawn from US Market March 2007)

Active Comparator: 2
Safinamide 100mg/day
Drug: Safinamide (as add-on therapy)
Safinamide add-on therapy with subjects with IPD treated with single dopamine agonist
Other Names:
  • Apokyn
  • Parlodel
  • Mirapex
  • Requip
  • Cabergoline (not approved in US)
  • Lisuride (not approved in US)
  • Pergolide (withdrawn from US Market March 2007)

Placebo Comparator: 3
Placebo 0mg/Safinamide
Drug: Safinamide (as add-on therapy)
Safinamide add-on therapy with subjects with IPD treated with single dopamine agonist
Other Names:
  • Apokyn
  • Parlodel
  • Mirapex
  • Requip
  • Cabergoline (not approved in US)
  • Lisuride (not approved in US)
  • Pergolide (withdrawn from US Market March 2007)

Primary Outcome Measures :
  1. Evaluate the changes from baseline to W24 in motor symptoms (UPDRS Section III). [ Time Frame: 24 weeks ]

Secondary Outcome Measures :
  1. Evaluate the changes from baseline to W24 in activities of daily living, cognition, change in global clinical status, responder rates with regard to motor symptoms and health related quality of life [ Time Frame: 24 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   30 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Diagnosis of idiopathic Parkinson's Disease of less than 5 years duration, with a Hoehn and Yahr stage of I-III. The diagnosis should be based on medical history and neurological examination.
  2. 30 to 80 years, inclusive, at screening.
  3. If female, be either post menopausal for at least 2 years, surgically sterilised or have undergone hysterectomy or, if of child bearing potential they must be willing to avoid pregnancy by using an adequate method of contraception for four weeks prior to, during and four weeks after the last dose of study medication. For the purposes of this study, women of childbearing potential are defined as all female subjects after puberty unless they are post-menopausal for at least two years, are surgically sterile or are sexually inactive.
  4. Receiving treatment with a single dopamine agonist at a stable dose for at least 4 weeks prior to the screening visit.
  5. Willing and able to participate in the study and have provided written, informed consent.

Exclusion Criteria:

To be eligible for inclusion in this study the subjects must not meet any of the following criteria:

  1. Any indication of forms of Parkinsonism, other than idiopathic Parkinson's Disease.
  2. If female, be pregnant or lactating.
  3. Current diagnosis of substance abuse or history of alcohol or drug abuse in the past 3 months.
  4. Currently experiencing end of dose wearing off or on-off phenomena, disabling peak dose or biphasic dyskinesias, or unpredictable or widely swinging fluctuations.
  5. Current clinically significant gastrointestinal, renal, hepatic, endocrine, pulmonary or cardiovascular disease, including acute gastric ulcer, hypertension that is not well controlled, asthma, chronic obstructive pulmonary disease (COPD), and Type I diabetes. Subjects with a history of gastric ulcer who have not had a recent episode of acute gastritis and are not currently experiencing gastric pain will be eligible for inclusion.
  6. Second- or third-degree atrioventricular block or sick sinus syndrome, uncontrolled atrial fibrillation, severe or unstable angina, congestive heart failure, myocardial infarction within 3 months of the screening visit, or significant ECG abnormality, including QTc ≥ 450 msec (males) or ≥ 470 msec (females), where QTc is based on Bazett's correction method.
  7. Have received treatment with safinamide previously.
  8. Concomitant disease likely to interfere with the study medication (e.g. capable of altering absorption, metabolism or elimination of the study drug).
  9. History of, or current psychosis (e.g. schizophrenia or psychotic depression) or a score ≥ 3 on item 2 (thought disorder) or 3 (depression) of the UPDRS, Section I at screening.
  10. Evidence of dementia or cognitive dysfunction, as indicated by a MMSE score < 24 or a score ≥ 3 on item 1 (mentation) of the UPDRS, Section I at screening.
  11. Depression, as indicated by a GRID-HAMD (17-item scale) score > 17 at screening.
  12. History of allergic response to anticonvulsants or anti-Parkinsonian agents.
  13. Mental or physical condition (e.g., neurotic behaviour, crippling degenerative arthritis, or limb amputation), which would preclude performing efficacy or safety assessments.
  14. Hypersensitivity or contraindications to MAO B inhibitors.
  15. Current history of severe dizziness or fainting on standing, due to postural hypotension.
  16. Neoplastic disorder, which is either currently active or has been in remission for less than one year.
  17. Participation in a clinical trial within 30 days of entry into the trial (screening visit) or has received treatment with any investigational compound within 30 days or 5 half-lives, whichever is longer, prior to screening.
  18. Treatment of their Parkinsonian symptoms with a medication, other than a stable dose of a single dopamine agonist, during the 8 weeks preceding the screening visit.
  19. Treatment with any agent known to significantly inhibit or induce drug-metabolising enzymes (e.g., barbiturates, phenothiazines, etc.) within 4 weeks preceding the screening visit.
  20. Treatment with opioids (e.g., tramadol, meperidine derivatives), SNRIs (e.g., venlafaxine, duloxetine), tri- or tetra-cyclic antidepressants, MAO inhibitors (e.g. selegiline), in the 8 weeks prior to the screening visit. Dextromethorphan will be permitted if used for treating cough.
  21. Treatment with a depot neuroleptic within one injection cycle, or oral neuroleptics within 4 weeks prior to the screening visit.
  22. Treatment with a drug that has hepatotoxic potential, e.g., tamoxifen, within 4 weeks, or received radiation therapy or a drug with cytotoxic potential, e.g., chemotherapy, within one year prior to the screening visit.
  23. Diagnosis of HIV, or tests positive for Hepatitis C antibodies, or Hepatitis B surface antigen.
  24. Any abnormality that the investigator deems to be clinically relevant, either on medical history, physical examination, ECG or in a diagnostic laboratory test.
  25. Ophthalmologic history including any of the following conditions: albino subjects, family history of hereditary retinal disease, progressive and/or severe diminution of visual acuity (i.e., 20/70), retinitis pigmentosa, retinal pigmentation due to any cause, any active retinopathy or ocular inflammation (uveitis), or diabetic retinopathy.
  26. Signs and symptoms suggestive of transmissible spongiform encephalopathy, or family members who suffer(ed) from such.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00605683

Show Show 125 study locations
Sponsors and Collaborators
Newron Pharmaceuticals SPA
Layout table for investigator information
Study Director: Jonathan Willmer, MD Merck Serono S.A., Geneva
Layout table for additonal information
Responsible Party: Newron Pharmaceuticals SPA Identifier: NCT00605683    
Other Study ID Numbers: 27918
EudraCT: 2007-002963-28
First Posted: January 31, 2008    Key Record Dates
Last Update Posted: October 29, 2013
Last Verified: March 2013
Additional relevant MeSH terms:
Layout table for MeSH terms
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases
Antiparkinson Agents
Anti-Dyskinesia Agents
Dopamine Agonists
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Protective Agents
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Autonomic Agents
Peripheral Nervous System Agents